G-CSF dosage and scheduling following autologous PBSC transplantation
In a recent paper in Bone Marrow Transplantation, Colby et al 1 reported their results from a retrospective analysis of G-CSF at a dose of 5 g/kg/day starting from day +1 post autologous PBSC transplant compared to delayed addition of G-CSF from day +4. Based upon previous studies in autologous bone marrow transplantation they reasoned that the delayed addition of G-CSF would be as effective as therapy given from day +1, but would result in financial savings. Indeed, a previous randomised study reported that delayed addition of G-CSF was as effective as early G-CSF following PBSC transplantation, 2 however, Colby et al found that the patients who received delayed addition of G-CSF from day ϩ4 had slower engraftment (10 days to an ANC Ͼ0.5 × 10 9 /l compared to 8.5 days). Despite the more prolonged course of G-CSF, the institutional transplant costs were lower in the patients receiving early (day ϩ1) G-CSF due to reduced hospitalisation and support costs.
Their paper raises the question of the most appropriate scheduling and dose of growth factors following autologous transplantation. As quoted by the authors, a number of studies have addressed this issue by means of randomised studies of growth factors compared to placebo (Table 1) and although the dosage of growth factor varied, all have demonstrated accelerated neutrophil engraftment. We recently reported a randomised study of low-dose G-CSF starting at day +1 following autologous PBSC in patients with lymphoproliferative disorders which showed a significantly accelerated neutrophil recovery compared to placebo, with a median time to an ANC Ͼ0.5× 10 9 /l of 10 days.
3 Our study used G-CSF at a dose of 50 g/m 2 , not 5 g/kg as quoted by Colby et al 1 in their paper. Although we have not performed a prospective comparison of low-dose vs standard-dose G-CSF therapy following PBSC transplantation, our results suggest that a significant reduction in G-CSF dosage can be achieved with comparable engraftment kinetics to conventional dosage G-CSF (Table 1) . In our study, the use of low-dose G-CSF resulted in a significant reduction in support and hospitalisation costs which would have been almost entirely negated if conventional dose G-CSF had been used (most patients required just three vials of filgrastim (300 g)). In summary therefore, although we agree with the authors that the use of early post-transplant G-CSF has clinical benefit, we suggest that this can be achieved with low-dose G-CSF thus maximising the economic advantages.
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Dr Spitzer replies:
We appreciate the comments of McQuaker and colleagues regarding our manuscript 'Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation'. The authors have cited their previously published study which demonstrated the advantage of G-CSF at a dose of 50 g per day compared to placebo following autologous peripheral blood stem cell transplan-
